Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Kamada ( (IL:KMDA) ) has shared an announcement.
On June 17, 2025, Kamada Ltd. announced that despite evolving circumstances in the Middle East, its operations and manufacturing at its Israeli facility continue uninterrupted, ensuring global product availability. Although Israeli airspace closures may temporarily affect shipments, Kamada’s distribution centers and partners worldwide have sufficient stock to meet demand, underscoring the company’s commitment to business continuity and employee well-being.
The most recent analyst rating on (IL:KMDA) stock is a Hold with a ILs13.00 price target. To see the full list of analyst forecasts on Kamada stock, see the IL:KMDA Stock Forecast page.
More about Kamada
Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapies. It offers a range of FDA-approved products for rare and serious conditions, including KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG®, and HEPAGAM B®. The company focuses on organic growth, business development, plasma collection, and advancing new product candidates.
Average Trading Volume: 77,354
Current Market Cap: ILs1.42B
See more data about KMDA stock on TipRanks’ Stock Analysis page.